- Home
- CHRS vs OBIO Comparison
CHRS vs OBIO Comparison
Compare CHRS & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- OBIO
- Stock Information
- Founded
- CHRS 2010
- OBIO 2017
- Country
- CHRS United States
- OBIO United States
- Employees
- CHRS N/A
- OBIO N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- CHRS Health Care
- OBIO Health Care
- Exchange
- CHRS Nasdaq
- OBIO Nasdaq
- Market Cap
- CHRS 185.5M
- OBIO 200.1M
- IPO Year
- CHRS 2014
- OBIO N/A
- Fundamental
- Price
- CHRS $1.52
- OBIO $4.79
- Analyst Decision
- CHRS Strong Buy
- OBIO Strong Buy
- Analyst Count
- CHRS 4
- OBIO 4
- Target Price
- CHRS $5.38
- OBIO $15.75
- AVG Volume (30 Days)
- CHRS 10.1M
- OBIO 64.0K
- Earning Date
- CHRS 11-06-2024
- OBIO 11-12-2024
- Dividend Yield
- CHRS N/A
- OBIO N/A
- EPS Growth
- CHRS N/A
- OBIO N/A
- EPS
- CHRS N/A
- OBIO N/A
- Revenue
- CHRS $304,340,000.00
- OBIO $2,647,000.00
- Revenue This Year
- CHRS $1.64
- OBIO $12.39
- Revenue Next Year
- CHRS $16.98
- OBIO $120.99
- P/E Ratio
- CHRS N/A
- OBIO N/A
- Revenue Growth
- CHRS 44.19
- OBIO N/A
- 52 Week Low
- CHRS $0.66
- OBIO $4.22
- 52 Week High
- CHRS $3.70
- OBIO $10.44
- Technical
- Relative Strength Index (RSI)
- CHRS 52.47
- OBIO 37.52
- Support Level
- CHRS $1.45
- OBIO $4.36
- Resistance Level
- CHRS $1.85
- OBIO $5.28
- Average True Range (ATR)
- CHRS 0.23
- OBIO 0.45
- MACD
- CHRS -0.03
- OBIO -0.07
- Stochastic Oscillator
- CHRS 3.88
- OBIO 23.65
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.